| NDC包装代码 | 产品NDC | 产品类型 | 商品名 | 通用名 | 剂型 | 给药途径 | 上市日期 | 结束日期 | 市场类别 | 申请号 | 标签持有者 | 活性成分 | 规格 | 包装描述 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0002-7797-61 | 0002-7797 | HUMAN PRESCRIPTION DRUG | EBGLYSS | lebrikizumab-lbkz | INJECTION, SOLUTION | SUBCUTANEOUS | 20240913 | N/A | BLA | BLA761306 | Eli Lilly and Company | LEBRIKIZUMAB | 250 mg/2mL | 1 SYRINGE in 1 CARTON (0002-7797-61) / 1 mL in 1 SYRINGE |
| 0002-7797-11 | 0002-7797 | HUMAN PRESCRIPTION DRUG | EBGLYSS | lebrikizumab-lbkz | INJECTION, SOLUTION | SUBCUTANEOUS | 20240913 | N/A | BLA | BLA761306 | Eli Lilly and Company | LEBRIKIZUMAB | 250 mg/2mL | 1 SYRINGE in 1 CARTON (0002-7797-11) / 1 mL in 1 SYRINGE (0002-7797-01) |
| 0002-7772-62 | 0002-7772 | HUMAN PRESCRIPTION DRUG | EBGLYSS | lebrikizumab-lbkz | INJECTION, SOLUTION | SUBCUTANEOUS | 20240913 | N/A | BLA | BLA761306 | Eli Lilly and Company | LEBRIKIZUMAB | 250 mg/2mL | 2 SYRINGE in 1 CARTON (0002-7772-62) / 1 mL in 1 SYRINGE |
| 0002-7772-11 | 0002-7772 | HUMAN PRESCRIPTION DRUG | EBGLYSS | lebrikizumab-lbkz | INJECTION, SOLUTION | SUBCUTANEOUS | 20240913 | N/A | BLA | BLA761306 | Eli Lilly and Company | LEBRIKIZUMAB | 250 mg/2mL | 1 SYRINGE in 1 CARTON (0002-7772-11) / 1 mL in 1 SYRINGE (0002-7772-01) |